SCHEMBL3596906

SCHEMBL3596906

CC1(C)OB(c2ccc(-c3sccc3N)cc2)OC1(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.55
LPL P06858 12/20 0.55
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
F11 P03951 2/20 0.40
SNCA P37840 1/20 0.37
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
ESR2 Q92731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3252928 0.81 LIPG (0.55) LIPGLPLCA1CA2CA9
SCHEMBL3126347 0.80 LIPG (0.54) LIPGLPLCA1CA2CA9
SCHEMBL3596902 0.80 LIPG (0.50) LIPGLPLCA1CA2CA9
SCHEMBL3129008 0.79 LIPG (0.52) LIPGLPLCA1CA2CA9
SCHEMBL24608995 0.75 LIPG (0.83) LIPGLPLCA1CA2CA9
SCHEMBL2707320 0.75 LIPG (0.83) LIPGLPLCA1CA2CA9
SCHEMBL228212 0.73 LPL (0.71) LIPGLPLCA1CA2CA9
SCHEMBL14946710 0.72 LPL (0.56) LIPGLPLF11SNCA
SCHEMBL55445 0.72 LPL (0.59) LIPGLPLCA1CA2CA9
SCHEMBL13699552 0.71 LIPG (1.00) LIPGLPLCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652064-B2 AMPA receptor potentiators ELI LILLY AND COMPANY (US) 2010-01-26 US disclosed
EP-1893597-B1 AMPA RECEPTOR POTENTIATORS LILLY CO ELI (US) 2008-11-12 EP disclosed
US-7393868-B2 AMPA receptor potentiators ELI LILLY AND COMPANY (US) 2008-07-01 US disclosed
EP-1893597-A2 AMPA RECEPTOR POTENTIATORS ELI LILLY AND COMPANY (US) 2008-03-05 EP disclosed
US-20070142441-A1 AMPA receptor potentiators ELI LILLY AND COMPANY 2007-06-21 US disclosed
WO-2006132811-A2 AMPA RECEPTOR POTENTIATORS ELI LILLY AND COMPANY (US) 2006-12-14 WO disclosed
US-20060276532-A1 AMPA RECEPTOR POTENTIATORS ELI LILLY AND COMPANY 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142441-A1 AMPA receptor potentiators GABRE, GRIN1, GRIK2 LIPG 4158/4885LPL 4139/4885CA1 522/4885
US-20060276532-A1 AMPA RECEPTOR POTENTIATORS GABRE, GRIN1, GRIK2 LIPG 4158/4885LPL 4139/4885CA1 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.